echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Biogen Alzheimer's FDA judgment date approaches capital market warning

    Biogen Alzheimer's FDA judgment date approaches capital market warning

    • Last Update: 2021-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The US FDA will make a decision on Biogen's aducanumab on June 7.


    And if rejected, it may have a profound impact on the Massachusetts-based company.


    Analyst Iuri Struta said in the study that Biogen lacks preparation for the patent cliffs of the three key multiple sclerosis drugs Tysabri, Tecfidera and Vumerity.


    At the same time, sales data show that the company's sales are declining rapidly.


    According to Struta, aducanumab is "the only real hope to avoid falling into the patent cliff.


    Insightia said that apart from these efforts, Bojian does not have enough measures to maintain sales before 2024.


    Insightia pointed out that since Vounatsos took over in 2017, Bojian has only made one acquisition, that is, the acquisition of Nightstar Therapeutics for US$800 million.


    It is not the first time for Bojian that activist investors have put pressure on the company.


    Before the FDA made a decision on aducanumab, Brian Abrahams of RBC Capital Markets has warned investors to be prepared, not only for substantial changes in Bojian’s stock, but also for other sales.


    Abrahams pointed out, “The FDA’s upcoming decision on aducanumab is not only critical for Bojian, but may also have repercussions in the entire biopharmaceutical field, affecting the overall sentiment in the field, regulatory flexibility, and business development dynamics.


    Finishing: Zhilin-Acorn

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.